Abstract
Protracted COVID-19 is increasingly recognised in immunocompromised patients, particularly those with haematological malignancies. Here, we present the case of a patient with protracted COVID-19 and an underlying B-cell malignancy. Standard COVID-19 treatment with remdesivir and steroids proved ineffective in this patient as she continued to have evolving ground-glass opacities on imaging. A multidisciplinary involvement altered treatment to include a combination of antivirals nirmatrelvir/ritonavir (Paxlovid) and remdesivir, a monoclonal antibody and immunoglobulins leading to a clinical cure. This report highlights the need for a more tailored approach in this patient sub-group than the rest of the population.